Zacks • 2 days ago
Alkermes (ALKS) reported a narrower-than-expected, second-quarter 2016 loss while revenues beat estimates; the company revised its outlook for 2016.
Associated Press • 3 days ago
On a per-share basis, the Dublin 4, Ireland-based company said it had a loss of 31 cents. Losses, adjusted for stock option expense and non-recurring costs, were 1 cent per share. The results surpassed ...
Insider Monkey • 4 days ago
Recro Pharma Inc (NASDAQ:REPH) is up more than 27% on Wednesday after announcing data from its lead acute pain trial. The company has developed an IV formulation of an already established drug, and is currently enrolling in the second of two pivotals that will form the basis of a New Drug Application if all runs smoothly. […]
Barrons.com • 5 days ago
Guggenheim Securities Acorda Therapeutics, Alkermes and Alexion Pharmaceuticals report second-quarter earnings on Thursday, July 28, before the market opens. We suspect Acorda (ticker: ACOR) (rated at ...
Capital Cube • last month
Click here to see latest analysisCapitalcube gives Alkermes Plc a score of 25.Our analysis is based on comparing Alkermes Plc with the following peers – Acorda Therapeutics, Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Novartis AG Sponsored ADR, Teva Pharmaceutical Industries Limited Sponsored ADR, Sanofi Sponsored ADR, Zogenix, Inc., Pfizer Inc. and Astrazeneca PLC Sponsored […] (Read more...) The post Alkermes Plc – Value Analysis (NASDAQ:ALKS) : June 21, 2016 appeared first on CapitalCube.
Capital Cube • last month
Click here to see latest analysis*Disclaimer : This is as of previous day’s closing price.Technical IndicatorsBelow is a quick look at 5 technical indicators for Alkermes Plc. More studies are available on the Technical Chart.IndicatorSignalClosing Price above/below 50 Day Moving AverageBearishClosing Price above/below 200 Day Moving AverageBearish50 Day Moving Average above/below 200 Day Moving AverageBearishRSI […] (Read more...) The post Alkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : June 20, 2016 appeared first on CapitalCube.
Capital Cube • 2 months ago
Click here to see latest analysis*Disclaimer : This is as of previous day’s closeETF’s with exposure to Alkermes PlcHere are 5 ETF’s with the largest exposure to ALKS-US. Comparing the performance and risk of Alkermes Plc with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns […] (Read more...) The post ETF’s with exposure to Alkermes Plc : June 8, 2016 appeared first on CapitalCube.
Market Realist • 2 months ago
Alkermes (ALKS) was the top performer within the mid-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB), rising 4.1% on May 27, 2016.
After hours: 49.910.01 (0.02%) as of 4:48 PM EDT
|Bid||45.00 x 100|
|Ask||65.10 x 100|
|52wk Range||27.14 - 80.71|
|Day's Range||48.28 - 50.06|
|Avg Vol (3m)||979,808|
As of 4:00 PM EDT. Market closed.